Recent Early Stage I-II (A-B) Prostate Cancer News

Data Demonstrates Benefit of Utilizing Multiple Biological Pathways to Predict Tumor Behavior in Prostate and Renal Cancers (June 9, 2014)

REDWOOD CITY, Calif., June 3, 2014 /PRNewswire/ – Genomic Health, Inc. (Nasdaq: GHDX) today announced results of two studies demonstrating the ability of its Oncotype DX® test and a new 16-gene... Continue Reading

Radical Prostatectomy Offers Long-Term Benefit Over Watchful Waiting in Early Prostate Cancer (May 22, 2014)

Researchers in Sweden recently reported in The New England Journal of Medicine that radical prostatectomy continues to show long-term benefits over watchful waiting in early prostate cancer. Follow up... Continue Reading

Recent Studies Find Oncotype DX® Can Reliably Predict Risk of Aggressive Prostate Cancer (May 22, 2014)

Based on findings from three separate studies, it appears that the 17-gene Oncotype DX® Genomic Prostate Score (GPS) can help predict disease aggressiveness in prostate cancer at the time of diagnosis... Continue Reading

Radical Prostatectomy Shows Significant Long-Term Benefit in Early Prostate Cancer (March 18, 2014)

Extended follow-up of the Scandinavian Prostate Cancer Group-4 trial (SPCG-4) has confirmed that radical prostatectomy is associated with a substantial reduction in mortality among men with early prostate... Continue Reading

High Incidence of Many Complications after Surgery or Radiation for Prostate Cancer (February 27, 2014)

Men who undergo surgery or radiation therapy for prostate cancer may face a variety of complications in addition to incontinence and erectile dysfunction—including high rates of hospitalization, urologic... Continue Reading

Long-Term Hormone Therapy Offers No Benefit in Intermediate-Risk Prostate Cancer (November 13, 2013)

Long-term hormone therapy after radiation treatment for intermediate-risk prostate cancer does not improve disease-specific or overall survival, according to the results of a study presented at the annual... Continue Reading

Metformin May Improve Survival in Diabetic Men with Prostate Cancer (September 4, 2013)

Diabetic men with prostate cancer lived significantly longer and were significantly less likely to die of prostate cancer when treated with metformin, an insulin-lowering drug, according to the results... Continue Reading

Advanced Treatments Increasingly Used Among Men with a Low Risk of Dying from Prostate Cancer (July 19, 2013)

The use of advanced treatment technologies for prostate cancer, such as intensity-modulated radiotherapy (IMRT) and robotic prostatectomy, has increased among men with low-risk disease—despite the fact... Continue Reading

ASTRO and AUA Issue Joint Guideline for Radiation After Prostate Surgery (June 19, 2013)

The American Society for Radiation Oncology (ASTRO) and the American Urological Association (AUA) have issued a joint guideline regarding the use of radiation therapy after prostatectomy. It marks the... Continue Reading

Study Compares Genomic Testing of Normal and Cancerous Prostate Tissue (June 12, 2013)

The Oncotype DX® prostate cancer test—which predicts the aggressiveness of early-stage prostate cancer and may help guide treatment decisions—is more predictive of outcome when used on tumor tissue... Continue Reading

Next Page »